J
Jennifer M. Specht
Researcher at University of Washington
Publications - 103
Citations - 1812
Jennifer M. Specht is an academic researcher from University of Washington. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 18, co-authored 84 publications receiving 1375 citations. Previous affiliations of Jennifer M. Specht include Seattle Cancer Care Alliance & Pacific Lutheran University.
Papers
More filters
Journal ArticleDOI
Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
Joyce O'Shaughnessy,Lee S. Schwartzberg,Michael A. Danso,Kathy D. Miller,Hope S. Rugo,Marcus Neubauer,Nicholas J. Robert,Beth A. Hellerstedt,Mansoor N. Saleh,Paul Richards,Jennifer M. Specht,D. A. Yardley,Robert W. Carlson,Richard S. Finn,Eric Charpentier,Ignacio Garcia-Ribas,Eric P. Winer +16 more
TL;DR: The trial did not meet the prespecified criteria for the coprimary end points of PFS and OS in the ITT population, and the potential benefit with iniparib observed in second-/third-line subgroup warrants further evaluation.
Journal ArticleDOI
Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer
Lisa K. Dunnwald,Julie R. Gralow,Georgiana K. Ellis,Robert B. Livingston,Hannah M. Linden,Jennifer M. Specht,Robert K. Doot,Thomas J. Lawton,William E. Barlow,Brenda F. Kurland,Erin K. Schubert,David A. Mankoff +11 more
TL;DR: LABC patients with limited or no decline in BF and FDG K(1) experienced higher recurrence and mortality risks that were greater than the effects of clinical tumor characteristics.
Journal ArticleDOI
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.
Shivani Srivastava,Scott N. Furlan,Scott N. Furlan,Carla A. Jaeger-Ruckstuhl,Megha Sarvothama,Carolina Berger,Kimberly S. Smythe,Sarah M. Garrison,Jennifer M. Specht,Jennifer M. Specht,Sylvia Lee,Sylvia Lee,Robert A. Amezquita,Valentin Voillet,Vishaka Muhunthan,Sushma Yechan-Gunja,Smitha P. S. Pillai,Christoph Rader,A. McGarry Houghton,Robert H. Pierce,Raphael Gottardo,David G. Maloney,David G. Maloney,Stanley R. Riddell,Stanley R. Riddell +24 more
TL;DR: In this paper, the authors adapted the KrasLSL-G12D/+;p53f/f autochthonous model of lung adenocarcinoma to express the CAR target ROR1.
Journal ArticleDOI
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer
Hannah M. Linden,Brenda F. Kurland,Lanell M. Peterson,Erin K. Schubert,Julie R. Gralow,Jennifer M. Specht,Georgiana K. Ellis,Thomas J. Lawton,Robert B. Livingston,Philip H. Petra,Jeanne M. Link,Kenneth A. Krohn,David A. Mankoff +12 more
TL;DR: FES PET can assess the in vivo pharmacodynamics of ER-targeted agents and may give insight into the activity of established therapeutic agents, including differences in the efficacy of blockade by different ER antagonists in current clinical use.
Journal ArticleDOI
Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
Jennifer M. Specht,Stephen L. Tam,Brenda F. Kurland,Julie R. Gralow,Robert B. Livingston,Hannah M. Linden,Georgiana K. Ellis,Erin K. Schubert,Lisa K. Dunnwald,David A. Mankoff +9 more
TL;DR: Changes in serial FDG PET may predict time-to-progression (TTP) and time to skeletal-related event (t-SRE) in BD metastatic breast cancer patients, but larger prospective trials are needed to validate changes inFDG PET as a surrogate endpoint for treatment response.